XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2018 - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Patel vs Galena biopharma, Inc
Patel vs Galena biopharma, Inc
Common Stock
Patel vs Galena biopharma, Inc
Additional Paid-In Capital
Secured Debt
Secured Debt
Common Stock
Secured Debt
Additional Paid-In Capital
Convertible Preferred Stock
Convertible Preferred Stock
Preferred Stock
Convertible Preferred Stock
Common Stock
Convertible Preferred Stock
Additional Paid-In Capital
Convertible Notes Payable
Convertible Notes Payable
Common Stock
Convertible Notes Payable
Additional Paid-In Capital
Beginning balance (in shares) at Dec. 31, 2017   0 5,766,891                              
Beginning balance at Dec. 31, 2017 $ 2,070 $ 0 $ 1 $ 56,254 $ (54,185)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Issuance of Stock (in shares)   10,700 6,845,000       228,672     715,277                
Issuance of Series A convertible preferred stock, net of offering costs 9,647     9,647                            
Issuance of stock, amount 21,564   $ 1 21,563   $ 1,250   $ 1,250 $ 2,896   $ 2,896              
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering (5,039)     (5,039)                            
Beneficial conversion feature arising from Series A convertible preferred stock (4,436)     (4,436)                            
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock 4,436     4,436                            
Issuance of common stock (in shares)   2,898 499,682                   (7,802) 3,748,184     118,644  
Convertible preferred stock dividends (487)     (487)                            
Issuance of common stock as result of conversion                       $ (8,654)     $ (8,654) $ 825   $ 825
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision 8,654     8,654                            
Impact of anti-dilution protection on liability-classified warrants (491)     (491)                            
Issuance of common stock in connection with warrant exchange agreements (in shares)     54,343                              
Issuance of common stock in connection with warrant exchange agreements 285     285                            
Issuance of common stock upon exercise of pre-funded warrants     2,524,783                              
Stock-based compensation 284     284                            
Net loss (14,347)       (14,347)                          
Ending balance (in shares) at Sep. 30, 2018   0 20,501,476                              
Ending balance at Sep. 30, 2018 $ 18,457 $ 0 $ 2 $ 86,987 $ (68,532)